Search

Search Results
Results 4181 - 4190 of 4527 for multiple sclerosis
  • Drug - 3 Oct 2024
    Consumer Medicine Information (CMI) about Terimide intended for persons living in Australia.
  • News - 17 Sep 2024
    Dr. Tilman explains the functions of iPSC-derived microglia and their relevance to conditions like Alzheimer’s.
  • News - 7 Aug 2024
    The night before her chemotherapy, Herlinda Sanchez sets out her clothes and checks that she has everything she needs: a blanket, medications, an iPad and chargers, a small Bible and rosary, fuzzy...
  • Drug - 1 Aug 2024
    Consumer Medicine Information (CMI) about Mavenclad intended for persons living in Australia.
  • Drug - 15 Jul 2024
    Consumer Medicine Information (CMI) about Gilenya intended for persons living in Australia.
  • Drug - 22 May 2024
    Consumer Medicine Information (CMI) about Solu-Medrol intended for persons living in Australia.
  • News - 22 Apr 2024
    In a discovery that could hasten treatment for patients with multiple sclerosis (MS), UC San Francisco scientists have discovered a harbinger in the blood of some people who later went on to develop...
  • Drug - 25 Mar 2024
    Consumer Medicine Information (CMI) about Triumeq intended for persons living in Australia.
  • News - 15 Mar 2024
    Globally, the number of people living with, or dying from, neurological conditions such as stroke, Alzheimer's disease and other dementias, and meningitis has risen substantially over the past 30...
  • Equipment - 22 Feb 2024
    Qunaterix's NF-LIGHTTM Neurofilament (NfL) Chain Assay can advance neurological research from the discovery stage to diagnosis using neurofilament light.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.